Evidence map›Paper›PMID 29860294›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018

Complementary Paths to Chagas Disease Elimination: The Impact of Combining Vector Control With Etiological Treatment.

Zulma M Cucunubá, Pierre Nouvellet, Jennifer K Peterson, Sarah M Bartsch, Bruce Y Lee, Andrew P Dobson, Maria-Gloria Basáñez

Open access · hybridAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. The Hidden Hand of Asymptomatic Infection Hinders Control of Neglected Tropical Diseases: A Modeling Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Cellular Stress and Senescence Induction duringTropical medicine and infectious disease · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Counting Down the 2020 Goals for 9 Neglected Tropical Diseases: What Have We Learned From Quantitative Analysis and Transmission Modeling?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Zulma M CucunubáLondon Centre for Neglected Tropical Disease Research, United Kingdom.
Pierre NouvelletLondon Centre for Neglected Tropical Disease Research, United Kingdom.
Jennifer K PetersonZoonotic Disease Research Center, Arequipa, Peru.
Sarah M BartschPublic Health Computational and Operations Research, John Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Bruce Y LeePublic Health Computational and Operations Research, John Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Andrew P DobsonDepartment of Ecology and Evolutionary Biology, Princeton University, New Jersey.
Maria-Gloria BasáñezLondon Centre for Neglected Tropical Disease Research, United Kingdom.
Johns Hopkins University · USLondon Centre for Neglected Tropical Disease Research · GBMedical Research Council · GBPrinceton University · USUniversity of Pennsylvania · US

Funding

Medical Research Council MR/R015600/1Medical Research Council MR/R024855/1
6 · The paper itself

Abstract

Background: The World Health Organization's 2020 goals for Chagas disease are (1) interrupting vector-borne intradomiciliary transmission and (2) having all infected people under care in endemic countries. Insecticide spraying has proved efficacious for reaching the first goal, but active transmission remains in several regions. For the second, treatment has mostly been restricted to recently infected patients, who comprise only a small proportion of all infected individuals. Methods: We extended our previous dynamic transmission model to simulate a domestic Chagas disease transmission cycle and examined the effects of both vector control and etiological treatment on achieving the operational criterion proposed by the Pan American Health Organization for intradomiciliary, vectorial transmission interruption (ie, <2% seroprevalence in children <5 years of age). Results: Depending on endemicity, an antivectorial intervention that decreases vector density by 90% annually would achieve the transmission interruption criterion in 2-3 years (low endemicity) to >30 years (high endemicity). When this strategy is combined with annual etiological treatment in 10% of the infected human population, the seroprevalence criterion would be achieved, respectively, in 1 and 11 years. Conclusions: Combining highly effective vector control with etiological (trypanocidal) treatment in humans would substantially reduce time to transmission interruption as well as infection incidence and prevalence. However, the success of vector control may depend on prevailing vector species. It will be crucial to improve the coverage of screening programs, the performance of diagnostic tests, the proportion of people treated, and the efficacy of trypanocidal drugs. While screening and access can be incremented as part of strengthening the health systems response, improving diagnostics performance and drug efficacy will require further research.

Indexed as

Disease EradicationModels, TheoreticalAnimalsChagas DiseaseHumansIncidenceInsect ControlInsecticidesInsect VectorsPrevalenceSeroepidemiologic StudiesTrypanocidal AgentsTrypanosoma cruziInsecticidesTrypanocidal Agents

Identifiers

PMID29860294
PMCPMC5982731
OpenAlexW2806949636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.